利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.016 秒)

    A METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A SUBJECT
    2.
    发明授权
    A METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A SUBJECT 有权

    公开(公告)号：EP2943792B1

    公开(公告)日：2018-11-14

    申请号：EP14700091.3

    申请日：2014-01-07

    申请人： SphingoTec GmbH

    发明人： BERGMANN, Andreas

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57488 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/74 ,  G01N2333/62 ,  G01N2333/70 ,  G01N2410/00

    摘要： Subject matter of the present invention is a method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject comprising: determining the level of Pro-Tachykinin, its splice variants or fragments thereof including Substance P and Neurokinin of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Tachykinin, its splice variants or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.

    A METHOD FOR PREDICTING THE RISK OF GETTING A MAJOR ADVERSE CARDIAC EVENT
    3.
    发明公开
    A METHOD FOR PREDICTING THE RISK OF GETTING A MAJOR ADVERSE CARDIAC EVENT 审中-公开
    VERFAHREN ZUR VORHERSAGE DES RISIKOS EINES MACE-EREIGNISSES

    公开(公告)号：EP3052941A1

    公开(公告)日：2016-08-10

    申请号：EP14777609.0

    申请日：2014-09-30

    申请人： SphingoTec GmbH

    发明人： BERGMANN, Andreas ,  NG, Leong

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2333/47 ,  G01N2800/324 ,  G01N2800/56

    摘要： Disclosed is a method for predicting the risk of getting a major adverse cardiac event or death in a subject that has suffered an acute myocardial infarction containing determining the level of Protachykinin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from the subject; and correlating the level of Protachykininor fragments thereof with the a risk for getting a major adverse cardiac event or death, wherein an elevated level is predictive for an enhanced risk of getting a major adverse cardiac event or death.

    摘要翻译： 公开了一种用于预测在患有急性心肌梗塞的受试者中获得主要不良心脏事件或死亡的风险的方法，所述急性心肌梗死包括测定从受试者获得的体液中至少5个氨基酸的Protachykinin或其片段的至少5个氨基酸 ; 并且将Protachykininor片段的水平与获得主要的不良心脏事件或死亡的风险相关联，其中升高的水平预示出获得主要不良心脏事件或死亡的风险增加。

    A METHOD FOR STRATIFYING A FEMALE SUBJECT FOR HORMONE REPLACEMENT THERAPY
    4.
    发明公开
    A METHOD FOR STRATIFYING A FEMALE SUBJECT FOR HORMONE REPLACEMENT THERAPY 审中-公开
    VERFAHREN ZUR STRATIFIZIERUNG EINER FRAU ZUR HORMONERSATZTHERAPIE

    公开(公告)号：EP3002589A1

    公开(公告)日：2016-04-06

    申请号：EP15187839.4

    申请日：2015-10-01

    申请人： sphingotec GmbH

    发明人： BERGMANN, Andreas ,  MELANDER, Olle

    IPC分类号： G01N33/574 ,  G01N33/74

    CPC分类号： G01N33/74 ,  G01N33/6893 ,  G01N2800/362

    摘要： Subject matter of the present invention is a method for stratifying a female subject for hormone replacement therapy comprising:
    • determining the level of Pro-Neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and
    • comparing said level of Pro-Neurotensin or fragments thereof with a pre-determined pro-NT threshold and
    • wherein in case the determined level of Pro-Neurotensin or fragments thereof is above said pre-determined threshold then the subject is identified as having an enhanced risk to suffer an adverse event or having an enhanced risk to attract a disease in case of a hormone replacement therapy, and
    • wherein in case the determined level of Pro-Neurotensin or fragments thereof is below said pre-determined threshold then the subject is identified as not having an enhanced risk to suffer an adverse event or as not having an enhanced risk to attract a disease in case of a hormone replacement therapy, and/or
    • determining the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids (pENK) in a bodily fluid obtained from said female subject; and
    • comparing said level of Pro-Enkephalin or fragments thereof with a pre-determined "pENK threshold" and
    • wherein in case the determined level of Pro-Enkephalin or fragments thereof is below said pre-determined pENK threshold then the subject is identified as having an enhanced risk to suffer an adverse event or having an enhanced risk to attract a disease in case of a hormone replacement therapy, and
    • wherein in case the determined level of Pro-Enkephalin or fragments thereof is above said pre-detennined pENK threshold then the subject is identified as not having an enhanced risk to suffer an adverse event or as not having an enhanced risk to attract a disease in case of a hormone replacement therapy.

    摘要翻译： 本发明的主题是用于分层雌激素替代疗法的雌性受试者的方法，包括：确定从所述雌性受试者获得的体液中至少5个氨基酸的Pro-Neurotensin或其片段的水平; 并且将所述Pro-Neurotensin或其片段的水平与预先确定的亲NT阈值和¢相比较，其中如果所确定的Pro-Neurotensin或其片段的水平高于所述预定阈值，则识别所述受试者 因为在激素替代治疗的情况下，具有增加的风险以遭受不良事件或增加吸引疾病的风险，而如果所确定的Pro-Neurotensin或其片段的水平低于所述预定阈值， 那么该受试者被鉴定为不具有增加的风险，以承受不良事件或在激素替代疗法的情况下不具有增强的吸引疾病的风险，和/或确定前脑啡肽或其片段的水平 在从所述女性受试者获得的体液中至少5个氨基酸（pENK）; 并且将所述Pro-Enkephalin或其片段的水平与预先确定的“pENK阈值”和“¢”进行比较，其中如果所确定的Pro-脑啡肽或其片段的水平低于所述预先确定的pENK阈值，则所述对象是 被鉴定为在激素替代治疗的情况下具有增加的风险以遭受不良事件或增加吸引疾病的风险，并且其中如果确定的Pro-脑啡肽或其片段的水平高于所述预先确定的 pENK阈值，则该受试者被鉴定为不具有增加的不利事件的风险或在激素替代疗法的情况下不具有增强的吸引疾病的风险。

    USE OF PRECURSORS OF ENKEPHALINS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTICS
    5.
    发明公开
    USE OF PRECURSORS OF ENKEPHALINS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTICS 有权
    前体脑啡肽和/或其片段在医疗诊断用途

    公开(公告)号：EP1745297A1

    公开(公告)日：2007-01-24

    申请号：EP05742347.7

    申请日：2005-05-11

    申请人： SphingoTec GmbH

    发明人： BERGMANN, Andreas ,  ERNST, Andrea

    IPC分类号： G01N33/94 ,  C07K16/00

    CPC分类号： C07K16/26 ,  G01N2333/70

    摘要： The invention relates to the diagnosis of components in human or animal body fluids, tissues and/or biomaterials. More specifically the invention relates to the use of precursors of enkephalins and/or its fragments isolated from body fluids, tissues or other biomaterials as marker peptide or medical diagnositics as well as for the diagnostic detection of the course prognosis and course control of diseases/disorders comprising diseases/disorders of the central nervous system, neurodegenerative diseases, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ischemia comprising myocardiac ishcemica, schizophrenia, diseases/disorders of the immune system, diseases/conditions of pain, chronic pain, migraine, tension type headache, tumor diseases/cancer comprising lymphoblastic leukaemia, malignant brain tumors, adenomas, in particular human pituitary adenomas, disorders of the blood brain barrier, multiple sclerosis, inflammation, chronic arthritis, infectious diseases, bacterial and viral infections, in particular infections of Gram-positive bacteria, borna diseases virus infections, peritonitis, intoxication, AIDS, stress, trauma comprising head trauma, infarction, in particular cerebral infarction, heart and cardiovascular diseases comprising coronary heart disease, bone and skin disorders, malaria chronic/obstructive pulmonary disease and cerebral damage. The invention further provides antibodies ofr binding to certain proteins and their fragments, more specifically proenkephalin and its fragments. In accordance with the invention, a kit useful for the above mentioned diagnosis is also provided.

    ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE
    7.
    发明公开
    ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE 审中-公开

    公开(公告)号：EP4231018A2

    公开(公告)日：2023-08-23

    申请号：EP23167412.8

    申请日：2017-07-07

    申请人： SphingoTec GmbH

    发明人： BERGMANN, Andreas ,  VOORS, Adriaan

    IPC分类号： G01N33/74

    摘要： Subject matter of the present invention is a method for a) diagnosing congestion or assessing or monitoring the extent of congestion in a subject or, b) predicting or determining or monitoring need of therapy or intervention or predicting or determining or monitoring the success of a therapy or intervention of congestion or guiding a therapy or intervention in a subject or, c) predicting decongestion or residual congestion after therapy or intervention of congestion in a subject or, d) assessing decongestion or residual congestion after therapy or intervention of congestion in a subject or, e) assessing the decision on hospital discharge of a subject, wherein said subject is subject having acute heart failure that is either new-onset AHF or acute decompensated HF or acute decompensated chronic HF or wherein said subject is a subject having chronic heart failure with worsening signs/symptoms of chronic heart failure and wherein Pro-Adrenomedullin or fragments thereof of at least 5 amino acids is used as an early surrogate marker for congestion.

    A METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT
    10.
    发明公开
    A METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT 有权
    VERFAHREN ZUR VORHERSAGE DES RISIKOS VON KREBS BEI EINER WEIBLICHEN PATIENTIN

    公开(公告)号：EP2904398A1

    公开(公告)日：2015-08-12

    申请号：EP13779755.1

    申请日：2013-10-01

    申请人： sphingotec GmbH

    发明人： BERGMANN, Andreas ,  MELANDER, Olle

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57415 ,  G01N33/57423 ,  G01N2333/665 ,  G01N2800/50

    摘要： Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.

    摘要翻译： 本发明的主题是用于预测在女性受试者中不患有癌症或替代性诊断癌症的女性受试者患癌症的风险的方法，包括：测定前脑啡肽或其片段的水平，包括Leu-脑啡肽 和在所述女性受试者获得的体液中至少5个氨基酸的Met-脑啡肽; 并且将所述水平的前脑啡肽或其片段与获得癌症的风险相关联，其中降低的水平预示出增加的癌症风险或替代性诊断癌症的风险，其中降低的水平与癌症的诊断相关。